1542. In Vitro Activity of Tigecycline against Commonly Isolated Pathogens of Skin and Skin Structure Infections in Latin America TEST 2011-2014
Session: Poster Abstract Session: Clinical Infectious Diseases: Soft Tissue Infections (ABSSSIs)
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • Pfizer_P29_Tigecycline_Skin and Skin Structure Infections_Latin America_IDSA 2015_v1_final [Read-Only].pdf (21.0 kB)
  • Background: Tigecycline has been approved for the treatment of complicated skin and skin structure infections (SSSIs) since 2006. Although target pathogens have not shown a propensity to develop resistance to tigecycline over this time period, continued monitoring of tigecycline's in vitro activity is prudent. In this study data from The Tigecycline Evaluation Surveillance Trial (TEST) were analyzed to assess the level of activity of tigecycline against bacterial groups from Latin America that can be associated with skin and wound infections.

    Methods: A total of 663 clinical isolates from SSSIs were collected and identified in 13 countries in Latin America from 2011 to 2014. Bacterial identifications and susceptibility testing (broth microdilution according to CLSI guidelines) were performed locally. Susceptibility to tigecycline was interpreted using FDA breakpoints as available. Organism collection, transport, confirmation of organism identification, and management of a centralized database were coordinated by International Health Management Associates, Inc. (Schaumburg, IL, USA). Results: Tigecycline activity is summarized in the following table:

    Organism

    n

    MIC50

    MIC90

    %S

    Acinetobacter spp.

    51

    0.5

    2

    na

    Enterobacter spp.

    95

    0.5

    2

    93.7

    Enterococcus faecalis

    57

    0.12

    0.25

    100

    Enterococcus faecium

    8

    0.06

    0.25

    100

    Escherichia coli

    113

    0.25

    0.5

    100

    Klebsiella pneumoniae

    62

    0.5

    1

    96.8

    Serratia spp.

    38

    1

    4

    89.5

    Staphylococcus aureus

    210

    0.12

    0.25

    100

    S. aureus, MRSA

    112

    0.12

    0.25

    100

    S. aureus, MSSA

    98

    0.12

    0.25

    100

    Streptococcus agalactiae

    29

    0.03

    0.25

    100

    na breakpoints not defined

    Conclusion: Tigecycline demonstrated potent in vitro activity against the various organism groups from Latin American SSSIs, including both gram-negative and gram-positive organisms. MIC90 values ranged from 0.25 - 4 mg/ml. These current finding indicate that tigecycline has maintained a high level of in vitro activity against a wide variety of species associated with skin and wound infections.

    Daryl Hoban, PhD1, Dan Sahm, PhD1, Douglas Biedenbach, MS1 and Heidi Leister-Tebbe, BSN2, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer, Inc., Collegeville, PA

    Disclosures:

    D. Hoban, IHMA, Inc.: Independent Contractor , Consulting fee

    D. Sahm, IHMA, Inc.: Independent Contractor , Consulting fee

    D. Biedenbach, IHMA, Inc.: Independent Contractor , Consulting fee

    H. Leister-Tebbe, Pfizer, Inc.: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.